Detail page

Knowledge Web

Person

Julia Michaeli (1996-)

Ärztin

Name	Julia Michaeli
Time	1996- (Date of birth and death)
Place	Bad Nauheim (Geburtsort) Deutschland
Gender	weiblich
Academic degree	Dr. med. (an der Medizinischen Fakultät Mannheim der Universität Heidelberg) (2023)
Profession	Ärztin (characteristic profession)
Variant	Julia Caroline Michaeli J. Michaeli Julia C. Michaeli
Related	Frauenklinik (München-Großhadern) Krebsforschung (Thema)
Further information	Department of Obstetrics and Gynaecology, LMU University Hospital, LMU Munich, Germany
Record type	Person
GND-Identifier	127911424X
Record ID	127911424X
Involved in show all Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany Über die Unterschiede zwischen arteriellen und venösen Endothelzellen in Bezug auf Entzündung und Entzündungsauflösung Testicular cancer follow-up costs in Germany from 2000 to 2015

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Julia Michaeli (1996-)

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

Über die Unterschiede zwischen arteriellen und venösen Endothelzellen in Bezug auf Entzündung und Entzündungsauflösung

Testicular cancer follow-up costs in Germany from 2000 to 2015